Clinical and Biochemical Profile of Women Presenting with Hirsutism and It’s Treatment Outcome-A Prospective Study

Title: Clinical and Biochemical Profile of Women Presenting with Hirsutism and It’s Treatment Outcome-A Prospective Study

Authors: Dr D.S.Bebincy, Dr S. A. Meena, Dr Devika

DOI: https://dx.doi.org/10.18535/jmscr/v5i5.51

Abstract

Background: Hirsutism is the excessive growth of terminal hair in androgen dependent areas of a woman’s body. It can be idiopathic or pathological. The treatment varies according to the cause of hirsutism.

Objectives: This study was done to evaluate the various causes of hirsutism by clinical methods and biochemical investigations and their outcome noted after treatment for six months. The treatment was given depending upon the cause of hirsutism.

Materials and Methods: We evaluated 73 subjects with hirsutism. The age group ranged from 15 to 51 years. The study was conducted at the department of Obstetrics and Gynecology, Kanyakumari Government Medical College, Asaripallam from January 2013to January 2016. Scoring of hirsutism was done using modified Ferriman-Gallwey scoring system. Scoring > 8 was considered as hirsutism. All the subjects were evaluated clinically and biochemically. OCP containing cyproterone acetate 2 mg and ethinyl estradiol 35 microgram was given for subjects with PCOD and idiopathic hirsutism and metformin was added if BMI was > 25 kg/m2.

Results: In this study, hirsutism was commonly seen between 20 and 31 years. The main cause of hirsutism was PCOD (63%). There were 4 subjects with androgen secreting ovarian tumours and one subject with late onset congenital adrenal hyperplasia. There existed a statistical significance between the PCOD and the non PCOD groups with respect to the complaints of infertility (p=0.012), menstrual irregularities (p=0.041) and weight gain (p=0.002). The outcome was evaluated in 64 subjects. There was a reduction in the scoring of hirsutism in both the PCOD (p=.000) and the non PCOD groups (p=0.001) after treatment for six months. The mean reduction in the scoring of hirsutism was 1 in the PCOD group and 1.18 in the non PCOD group. There was also a significant reduction in weight in both the groups after treatment (p=0.000).

Conclusion: Though hirsutism is a cosmetic problem, it also causes psychological insult to a woman. It can also be a manifestation of an underlying health problem. It can also be idiopathic. Hence women with hirsutism should be evaluated completely and given treatment based upon the cause.

Keywords: Hirsutism, modified Ferriman-Gallwey scoring, androgen, PCOD, non PCOD, tumours, virilization, free testosterone, infertility, Cyproterone acetate, Ethinyl Estradiol, Metformin

References

1. Avner Hershlag, C Mathew Peterson. Hyperandrogenism from the Textbook of Novaks Gynecology Thirteenth edition 871-896

2. Leon Speroff, Glass RH,Kase NG. Amenorrhea in Clinical endocrinology and infertility 8^th edition 533-565

3. Melissa H, Hunter, Peter, Carek . Evaluation and treatment of women with hirsutism..American Family physician 2003 Jun 15;67 (12) 2565-2572

4. Information from Leung AK, Robson WL Hirsutism. International Journal of Dermatology 1993;32:773-7

5. Dorte Glintborg, Mariana Anderson. An update on the pathogenesis, inflammation and metabolism in hirsutism and polycystic ovarian syndrome. Gynecol Endocrinol April 2010; 26(4):281-296

6. PCOS and hyperandrogenism from the Textbook of Williams Gynecology. 1^st edition 383-399.

7. Pritts EA. Treatment of the infertile patient with PCOS. Obstet. Gynecol Sur. Sept 2002; 57(9):587-597.

8. Dunaif A Hyperandrogenic anovulation PCOS: a unique disorder of insulin action associated with an increased risk of non-insulin dependent diabetes mellitus. American Journal of Medicine– Jan 16 1995; 98 (IA 335 -39)

9. Convay G S, Agarwal R, Betteridge DJ and Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the PCOS. Clinical endocrinology.1992;37:119-125

10. Ancuta Gheorghisan-Galateanu, Simona Fica et al., Sertoli leydig cell tumour- a rare androgen secreting tumour in postmenopausal women-case report and review of literature. Journal of Cellular and Molecular Medicine, October 2003, Volume issue 4, page 461 – 471

11. Kozloviene D, Kazanavisius G, Kruminis V. The evaluation of clinical signs and hormonal changes in women who complained of excess hair growth. Clinic of Endocrinology, Kaunas University of Medicine, Eiveniu Z, 50009 Kaunas, Lithuania. daliakozloviene@one

12. Escobar-Morreale HF, San Mill et al., A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. Journal of Clinical Endocrinological Metabolism 2008 Feb; 93(2) 527-33. Epub 2007 Nov 13

13. Carmina E, Rosato F,Janni A et al., A risk-benefit assessment of pharmacological therapies for hirsutism. Journal of Clinical Endocrinological Metabolism 2006 Jan; 91(1):2-6 Epub 2005 Nov 1

14. Azziz R, Sanchez LA, Knochenhauer ES et al. Androgen excess in women. Journal of Clinical Endocrinological Metabolism 2004 Feb; 89(2):453-62

15. Pekhlivanov B, Mitkov M, Kavurdzhikova S Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome available from

16. http://www.zwomenshealth.com/images/hirsuitism-flowchart.gif

17. Carmina E, Lobo RA et al., The addition of dexamethasone to antiandrogen prolongs the duration of remission for hirsutism. Journal of Fertility and Sterility. 1998 Vol 69(6) (75-1079).

18. Venturoli S, Marescalchi O, Colombo FM, Macrelli, Ravoiolli B, Bagnoli A, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole and cyproterone acetate-estrogen regimen in the treatment of hirsutism. J Clin Endocrinological Metab 1999;84 : 1304-10.

19. Seaman HE, DeVries, Farmer RD. Venous thromboembolism associated with cyproterone acetate in combination with ethinyl estradiol(Dianette)- observation studies using the UK general practice research database. Int J Gynecol Obstet.2004 Oct;87(1):29-33

20. Vanderspuy ZM, Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. 2003;(4):CD001125

21. Falsetti L, Gambera A, Tisi G. Efficacy of the combination-ethinyl estradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in PCOS. Human Reprod 2001 Jan, 16(1);36-42

22. Aesha Sadaf,Hameed, Riswan et al. Journal of Pakistan Association of dermatologists 2006; 16: 69-73 Comparative analysis between ethinyl estradiol plus cyproterone acetate with or without metformin therapy in the treatment of polycystic ovarian syndrome induced hirsutism

23. V ATAY, C CAM, M MUHCU, H CAM, KARATEKA. A comparison of Letrozole and clomiphene citrate in women with PCOS undergoing ovarian stimulation. Journal of Int Med Reso.2006;34:73-76.

24. Moltz L , Trapp M, Bispink G et al. Rational hormonal diagnosis of secondary amenorrhea. (Journal Article )Geburtshilfe Frauenheilkd 1987 April ; 47(4) 2228-39

25. Ferriman DM, Gallwey JD clinical assessment of body hair growth in women. Journal of Clinical Endocrinological Metabolism 1961;144-147

26. Rotterdam ESHRE, ASRM – Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil steril 2004; 81:19 -25

27. Rosiglitazone and ethinyl estradiol/ cyproterone acetate as single and combined treatment of overweight women with polycystic ovarian syndrome and insulin Resistance. .Human Reproduction.2006 Jan ;21(1)121-8

28. Bergfeld WF hirsutism in women. Effective therapy that is safe for long term use . Postgrad Med Jun 2000; 107(7) 93 -4, 99 – 104

29. Koulori O, Konway GS A systematic medical treatment for hirsutism in women. Clinical Endocrinol (Oxf) 2008 May 2008 ;68(5) 800-5

30. Waggoner W, Boots LR, Aziz R.Total testosterone and DHEAS levels as predictors of androgen – secreting neoplasms a populational study. Gynaecological Endocrinology 1999 Dec; 13: 394 - 400

31. ARMSTRONG DT, DORRINGTON JH 1977. Estrogen biosynthesis in the ovaries and testis. Adv sex horm res 3: 217 -258

32. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of Diabetes, impaired fasting glucose, and impaired glucose tolerance in US Adults: The Third National Health and Nutrition Examination Survey, 1998-1994. Diabetes care. 1998;21:518-5

33. Erickson GF, MAGOFFIN DA, DYER CA et al, Ovarian androgen producing cells: a review of structure of function relationship Endocr Rev 1985; 6: 371 – 399.

34. Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv. Nov 2002; 57(11):755-67

35. POLSON DW, WADSWORTH J, ADAMS J AND FRANKS S 1988 PCOS: A common finding in normal women lancet 11: 870 - 872

36. BALEN AH et al: 1995. PCOS The spectrum of disorders in 1741 patients. Human rep 10: 2705 -2712

37. WALLEN F 1999 PCOS: Clinical perspeches Management obstet. Gynaecol survey 54: 403 – 411

38. Information from Gilchrist VJ, Hecht Br. A practical approach to hirsutism. American Family physician 1995;52

Abstract

References

Corresponding Author

Call For Paper Volume 12 Issue 10 November 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles

Search

Abstract

Call For Paper Volume 12 Issue 10 November 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles